CaltechAUTHORS
Published December 2022 | Version public
Journal Article Metadata-only

Lessons from the pandemic: Responding to emerging zoonotic viral diseases — a Keystone Symposia report

Creators

  • 1. ROR icon National Institute of Allergy and Infectious Diseases
  • 2. ROR icon Coalition for Epidemic Preparedness Innovations
  • 3. ROR icon Bernhard Nocht Institute for Tropical Medicine
  • 4. ROR icon The University of Texas Medical Branch at Galveston
  • 5. ROR icon California Institute of Technology
  • 6. ROR icon National Institute of Virology
  • 7. ROR icon University of Massachusetts Amherst
  • 8. ROR icon Duke NUS Graduate Medical School
  • 9. ROR icon University of Calgary
  • 10. ROR icon University of Oxford
  • 11. ROR icon World Health Organization
  • 12. ROR icon Colorado School of Public Health
  • 13. ROR icon University of Colorado Anschutz Medical Campus
  • 14. ROR icon EcoHealth Alliance
  • 15. ROR icon Microsoft (United States)
  • 16. ROR icon Foundation for Innovative New Diagnostics
  • 17. ROR icon Centers for Disease Control and Prevention
  • 18. ROR icon Johns Hopkins University
  • 19. ROR icon Duke Medical Center
  • 20. ROR icon University of Manitoba
  • 21. ROR icon Icahn School of Medicine at Mount Sinai
  • 22. ROR icon Lund University
  • 23. ROR icon La Jolla Institute For Allergy & Immunology
  • 24. ROR icon Harvard University
  • 25. ROR icon Zalgen (United States)
  • 26. ROR icon Institut Pasteur
  • 27. ROR icon International Center for Infectiology Research
  • 28. ROR icon École Normale Supérieure de Lyon
  • 29. ROR icon Oswaldo Cruz Foundation
  • 30. ROR icon University of Siena
  • 31. ROR icon Bill & Melinda Gates Foundation

Abstract

The COVID‐19 pandemic caught the world largely unprepared, including scientific and policy communities. On April 10–13, 2022, researchers across academia, industry, government, and nonprofit organizations met at the Keystone symposium "Lessons from the Pandemic: Responding to Emerging Zoonotic Viral Diseases" to discuss the successes and challenges of the COVID‐19 pandemic and what lessons can be applied moving forward. Speakers focused on experiences not only from the COVID‐19 pandemic but also from outbreaks of other pathogens, including the Ebola virus, Lassa virus, and Nipah virus. A general consensus was that investments made during the COVID‐19 pandemic in infrastructure, collaborations, laboratory and manufacturing capacity, diagnostics, clinical trial networks, and regulatory enhancements — notably, in low‐to‐middle income countries — must be maintained and strengthened to enable quick, concerted responses to future threats, especially to zoonotic pathogens.

Additional Information

Funding Information: National Institute of Allergy and Infectious Diseases; Canadian Medical Association; Public Health Agency of Canada; Robert Koch Institute; German Federal Ministry of Health COVID-19 Research and Development; WHO Solidarity Response Fund R.K.A. and M.V.K. presented work funded by the WHO Solidarity Response Fund and the German Federal Ministry of Health COVID‐19 Research and Development. R.K.A. would also like to thank the following additional funders of SeroTracker's SARS‐CoV‐2 evidence synthesis efforts: the Public Health Agency of Canada through Canada's COVID‐19 Immunity Task Force, the Robert Koch Institute, and the Canadian Medical Association Joule Innovation Fund. M.V.K. is employed by the WHO; the authors alone are responsible for the views expressed in this publication and they do not necessarily represent the decisions, policies, or views of WHO. E.d.W. and N.v.D. are supported by the Intramural Research Program of NIAID, NIH.

Additional details

Identifiers

PMCID
PMC9538336
Eprint ID
117477
Resolver ID
CaltechAUTHORS:20221017-15547800.42

Funding

National Institute of Allergy and Infectious Diseases
Canadian Medical Association
Public Health Agency of Canada

Dates

Created
2022-10-21
Created from EPrint's datestamp field
Updated
2023-01-25
Created from EPrint's last_modified field

Caltech Custom Metadata

Caltech groups
COVID-19